Stockscreener 앱 받기
1.89
1.05%
-0.02
시간 외 거래:
1.92
0.03
+1.59%
전일 마감가:
$1.91
열려 있는:
$1.94
하루 거래량:
262.28K
Relative Volume:
0.90
시가총액:
$11.45M
수익:
$1.38M
순이익/손실:
$-179.05M
주가수익비율:
-0.3078
EPS:
-6.14
순현금흐름:
$-155.03M
1주 성능:
-6.44%
1개월 성능:
+18.12%
6개월 성능:
+427.93%
1년 성능:
+61.54%
1일 변동 폭
$1.88
$1.95
1주일 범위
$1.86
$2.27
52주 변동 폭
$0.16
$6.83
바이오엑셀 테라퓨틱스 Stock (BTAI) Company Profile
명칭
Bioxcel Therapeutics Inc
전화
203-643-8060
주소
555 LONG WHARF DRIVE, NEW HAVEN, CT
BTAI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.89 | 12.23M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오엑셀 테라퓨틱스 Stock (BTAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-08-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-07-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-01 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-06 | 재확인 | BofA Securities | Buy |
| 2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-02-01 | 개시 | UBS | Buy |
| 2020-10-30 | 개시 | Goldman | Buy |
| 2020-09-02 | 개시 | Jefferies | Buy |
| 2020-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-04 | 개시 | Guggenheim | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
모두보기
바이오엑셀 테라퓨틱스 주식(BTAI)의 최신 뉴스
BioXcel Therapeutics Inc. Stock Analysis and ForecastRecord-breaking capital gains - Autocar Professional
What drives BioXcel Therapeutics Inc. stock priceSky-high return potential - Autocar Professional
What analysts say about BioXcel Therapeutics Inc. stockHigh-octane investment gains - Autocar Professional
Bioxcel Therapeutics' Strategic Move to Expand IGALMI for At-Home Use: Assessing the Market Opportunity and Regulatory Pathway for First-in-Class Agitation Treatment in Outpatient Mental Health - AInvest
BioXcel schedules FDA meeting for IGALMI outpatient use expansion - Investing.com Australia
BTAI files pre-sNDA to expand IGALMI label for home use | BTAI SEC FilingForm 8-K - Stock Titan
BioXcel Therapeutics Submits Pre-Supplemental New Drug - GlobeNewswire
First-Ever At-Home Agitation Drug: FDA to Review IGALMI for 23M Patient Market Opportunity - Stock Titan
Is BioXcel Therapeutics Inc. a good long term investmentRobust investment performance - PrintWeekIndia
How high can BioXcel Therapeutics Inc. stock price go in 2025Capital Growth Picks - beatles.ru
why bioxcel therapeutics inc. stock attracts strong analyst attentionStable Growth Stock Picks - Newser
What makes BioXcel Therapeutics Inc. stock price move sharplyAI Powered Stock Call - Newser
BioXcel Therapeutics Receives Steady Buy Rating from Lucid Capital Markets, Price Target Unchanged at $66.00 - AInvest
BTAI: BioXcel Therapeutics Receives Steady Buy Rating from Lucid Capital Markets | BTAI Stock News - GuruFocus
BioXcel Therapeutics (BTAI) Gains Patent Approval, Price Target Affirmed | BTAI Stock News - GuruFocus
BioXcel Therapeutics receives USPTO allowance for new Igalmi dosing patent By Investing.com - Investing.com South Africa
BioXcel Therapeutics receives USPTO allowance for new Igalmi dosing patent - Investing.com Nigeria
BioXcel Granted Patent for Dexmedetomidine Use - TipRanks
Why BioXcel Therapeutics Inc. stock attracts strong analyst attentionConsistent High Return Strategy - Newser
BioXcel wins USPTO nod; 14th Igalmi patent secures exclusivity to 2043 | BTAI SEC FilingForm 8-K - Stock Titan
How BioXcel Therapeutics Inc. stock performs during market volatilityProtected Capital Trading Plan - Newser
BioXcel Therapeutics, Inc. (BTAI) Retains Buy Rating on Positive Trial Progress - Insider Monkey
12 Best Fundamentally Strong Penny Stocks to Invest in - Insider Monkey
SHAREHOLDER ALERT: Potential Recovery for BioXcel Therapeutics, Inc. (BTAI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
NIP Group, Hyatt, BioXcel Therapeutics - TradingView
BioXcel Therapeutics rises on positive schizophrenia drug trial recommendation - TradingView
Why BioXcel Therapeutics Is Rising In Pre-market? - Nasdaq
BioXcel’s BXCL501 agitation treatment trial continues after safety review By Investing.com - Investing.com Canada
BioXcel’s BXCL501 agitation treatment trial continues after safety review - Investing.com
Bioxcel Receives Second Positive Recommendation To Continue Phase 3 Trial For Treatment Of Agitation Associated With Schizophrenia - TradingView
BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - TradingView
Bioxcel Therapeutics Plunges 11.71% Post Reverse Split - AInvest
Lucid Capital Sees Promising Future for BioXcel Therapeutics (BT - GuruFocus
Is BioXcel Therapeutics, Inc. overvalued or undervalued? - MarketsMojo
BioXcel stock price target raised to $8 from $3 at H.C. Wainwright - Investing.com India
BioXcel Therapeutics Requests to Dismiss Class Action Filed by Investors - TradingView
Real-World Deployments Signal AI Healthcare Is Ready for Scale - FinancialContent
BioXcel Therapeutics stock hits 52-week low at $1.24 By Investing.com - Investing.com South Africa
BioXcel Therapeutics stock hits 52-week low at $1.24 - Investing.com Australia
BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement - Revista ADVFN
BioXcel Therapeutics Receives Positive Recommendation from Data - GuruFocus
Class Suit Against AI Drugmaker Back On After Mediation Fails - Law360
BTAIBioXcel Therapeutics Provides Clinical and Business Update - mx.advfn.com
BioXcel’s Phase 3 trial of BXCL501 continues as advised by DSMB - Investing.com India
BioXcel Therapeutics (BTAI) Granted Extension to Retain Nasdaq L - GuruFocus
BioXcel Therapeutics granted Nasdaq extension - Investing.com Australia
바이오엑셀 테라퓨틱스 (BTAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):